Compare Emerson Electric Co. (EMR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs TG Therapeutics Inc — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Emerson Electric Co. is far larger — about 10.9× TG Therapeutics Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and TG Therapeutics Inc for 16 Days on average.
| EMR | TGTX | |
|---|---|---|
Market Cap | $88.72B | $8.16B |
Volume | 2,355,255 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $164.38 | $59.06 |
52-Week Low | $123.30 | $26.94 |
Typical Hold Time | 81 Days | 16 Days |
Enterprise Value | $99.80B | $8.37B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.06, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $165.90. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.84. Strong profitability is evident with a 53.16% gross margin and 13.83% net income margin, though valuation multiples like a P/E of 34.81 appear elevated. Recent news highlights momentum and Wall Street optimism.
EMR presents a favorable outlook with earnings momentum and analyst support, but risks include high valuation sensitivity and debt level increases. The stock offers potential upside to the price target, balanced by execution risks in a competitive industrial sector. Investors should weigh solid fundamentals against premium pricing.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
